Research guides

N-Acetyl Selank Amidate: what the research says

Selank with both termini capped, and the same evidence problem as its Semax counterpart: a plausible stability modification nobody has published a study on.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

This article is the Selank counterpart of the N-Acetyl Semax Amidate one, and the structure of the evidence problem is identical. The molecule is a modification of a peptide that has a literature; the modification itself does not.

What the molecule is

Selank with an acetyl cap at the N-terminus and an amide at the C-terminus. The seven-residue tuftsin-derived core is unchanged.

The rationale, and its limit

As with the Semax amidate, the terminal caps are a stability modification rather than a change of mechanism, intended to resist enzymatic breakdown while leaving the underlying activity intact. That is standard peptide chemistry and a reasonable design choice.

What makes it an inference rather than a finding is that nothing published measures either half of it for this molecule: not that the capped peptide persists longer, and not that its activity is unchanged. Selank's own literature is already thinner in English than it is in Russian, so the modified version inherits a partial evidence base and then adds an untested step on top of it.

Why this matters more than it sounds

Selank's defining reported property is a comparative one — anxiolytic activity without the sedation that accompanies benzodiazepines. A comparative property is exactly the kind that a change in distribution or receptor interaction could alter without abolishing activity altogether. Assuming it survives terminal capping is a larger assumption than assuming a simple efficacy claim does.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

  • Both citation lists are empty because no published study was found investigating this modified molecule. The literature cited for it in practice is Selank's.
  • No pharmacokinetic study demonstrates that the capped form persists longer than Selank. That durability is the reason for the modification and it is uncited.
  • Whether the capping leaves Selank's pharmacology unchanged has not been tested. The specific property at issue — anxiolytic activity without sedation — is comparative, and comparative properties are more fragile under a change in distribution than simple ones.
  • Selank itself has no randomised trial published in a Western-indexed journal, so the parent evidence this molecule borrows from is already limited in English.
  • It holds no marketing authorisation anywhere, and unlike Selank it is not a registered medicine in Russia either.
  • No safety data specific to this molecule has been published.

Common questions

Is N-Acetyl Selank Amidate better than Selank?
No published study compares them. The capping is intended to slow enzymatic clearance, which would change duration rather than potency, and that has not been demonstrated for this molecule.
Why cap both ends of the peptide?
Exopeptidases degrade peptides from the termini, so blocking both ends is a standard way of slowing breakdown. It is a durability modification, not a mechanistic one.
Does the Selank research apply?
By assumption only. Selank's key reported property is anxiolytic activity without sedation — a comparative claim, and the kind most vulnerable to a change in distribution or receptor interaction. Nothing published tests whether it survives capping.
Has this molecule been tested in humans?
No published study of the modified molecule was found in any model, human or animal.
Is it approved anywhere?
No. It is supplied as a laboratory reagent for in-vitro research and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

Related articles

  • Selank (TP-7): what the research says

    A tuftsin-derived anxiolytic registered as a medicine in Russia. Its defining reported property is what it lacks: sedation. The rodent evidence, and the limits.

  • N-Acetyl Semax Amidate: what the research says

    A terminally capped Semax with no literature of its own. What the capping is meant to do, and why every claim about it is borrowed from a different molecule.

  • Peptide shelf life and stability

    How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.

All guides